Department of Engineering and Science, University of Greenwich, London, UK.
Department of Engineering and Science, School of Computing and Mathematical Sciences, University of Greenwich, Old Royal Naval College, London, UK.
Pharm Dev Technol. 2024 Oct;29(8):793-804. doi: 10.1080/10837450.2024.2395422. Epub 2024 Aug 24.
The increasing prominence of biologics in the pharmaceutical market requires more advanced delivery systems to deliver these delicate and complex drug molecules for better therapeutic outcomes. Fibre technology has emerged as a promising approach for creating controlled and targeted drug delivery systems. Fibre-based drug delivery systems offer unprecedented opportunities for improving drug administration, fine-tuning release profiles, and advancing the realm of personalized medicine. These applications range from localized delivery at specific tissue sites to systemic drug administration while safeguarding the stability and integrity of delicate therapeutic compounds. Notwithstanding the promise of fibre-based drug delivery, several challenges such as non-scalability impede cost-effectiveness in the mass production of fibre systems. Biocompatibility and toxicity concerns must also be addressed. Furthermore, issues relating to stability, in-vitro in-vivo correlations, degradation rates, and by-product safety present additional hurdles. Pharmacoinformatics shows the impact of technologies in pharmaceutical processes. Emerging technologies such as Artificial Intelligence (AI) are a transformative force, progressively being applied to enhance various facets of pharmacy, medication development, and clinical healthcare support. However, there is a dearth of studies about the integration of AI in facilitating the translation of predominantly lab-scale pharmaceutical technologies into real-world healthcare interventions. This article explores the application of AI in fibre technology, its potential, challenges, and practical applications within the pharmaceutical field. Through a comprehensive analysis, it presents how the immense capabilities of AI can be leveraged with existing fibre technologies to revolutionize drug delivery and shape the future of therapeutic interventions by enhancing scalability, material integrity, synthesis, and development.
生物制剂在药物市场中的地位日益突出，这就需要更先进的输送系统来输送这些精细而复杂的药物分子，以获得更好的治疗效果。纤维技术已成为创建可控和靶向药物输送系统的有前途的方法。基于纤维的药物输送系统为改善药物管理、微调释放特性和推进个性化医疗领域提供了前所未有的机会。这些应用范围从特定组织部位的局部输送到系统药物输送，同时保护脆弱治疗化合物的稳定性和完整性。尽管基于纤维的药物输送具有很大的潜力，但一些挑战，如非扩展性，阻碍了纤维系统大规模生产的成本效益。生物相容性和毒性问题也必须得到解决。此外，与稳定性、体外-体内相关性、降解速率和副产物安全性相关的问题也带来了额外的障碍。药物信息学展示了技术在药物工艺中的影响。人工智能 (AI) 等新兴技术是一种变革力量，正逐步应用于增强药学、药物开发和临床医疗支持的各个方面。然而，关于人工智能在促进主要在实验室规模的药物技术转化为现实医疗干预方面的应用的研究还很少。本文探讨了人工智能在纤维技术中的应用、其潜力、挑战和在制药领域的实际应用。通过全面分析，展示了人工智能的巨大功能如何与现有的纤维技术相结合，以通过增强可扩展性、材料完整性、合成和开发来彻底改变药物输送并塑造治疗干预的未来。
